HCV protease inhibitors and uses thereof

US8497275B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Brian E. Green · Wonder Lake, US
• David D. Anderson · Kenosha, US
• Todd D. Bosse · Chicago, US
• Curt S. Cooper · Vernon Hills, US
• Larry L. Klein · Lake Forest, US
• Allan C. Krueger · Gurnee, US
• Daniel P. Larson · Highland Park, US
• Dachun Liu · Vernon Hills, US
• Keith F. McDaniel · Wauconda, US
• Christopher E. Motter · Oak Creek, US
• John K. Pratt · Kenosha, US
• Todd W. Rockway · Gurnee, US
• Teresa A. Rosenberg · Gurnee, US
• Ming C. Yeung · Grayslake, US
• Hui-Ju Chen · Grayslake, US
• Jason P. Shanley · Chicago, US

Key dates

• Filing date: Jun 26, 2009
• Grant date: Jul 30, 2013
• Expiry date: Feb 9, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K7/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.